The FDA has issued an emergency use authorization (EUA) for the IV drug Peramivir in children and adults hospitalized with (suspected or confirmed) H1N1. This drug should be used in patients who have not responded (or are not expected to respond) to oral or inhaled anti-viral therapy, or for which the provider determines that IV therapy is appropriate and warranted. Clinicians considering it’s use should read this (Fact Sheet)
Share This Post
Categories
Related Posts
During the first two to three weeks of the pandemic in 2020, I was involved in a lot of meetings about the current status and future plans for the impending surge of COVID-19 patients we were anticipating. It was during that time we witnessed COVID-19 ravaging cities like New York City. In one of the […]
The COVID-19 pandemic has changed health care as we know it. It has sowed fear and doubt among the public and created endless questions without answers. Our hospitalized patients may wonder why they can’t have their families beside them and worry about contracting the virus in the hospital. Strict visitation policies only add to their […]
This article is part of a series in The Hospital Leader written by members of the Division of Hospital Medicine at Dell Medical School at The University of Texas in Austin, exploring lessons learned from the coronavirus pandemic and outlining an approach for creating COVID-19 Centers of Excellence. During the early months of the COVID-19 […]
Leave A Comment